您的位置: 首页 > 农业专利 > 详情页

COMPLEXES D'ANTICORPS MULTIVALENTS CIBLANT L'IGF-1R PRÉSENTANT UNE PUISSANTE TOXICITÉ CONTRE LES TUMEURS SOLIDES
专利权人:
INC.;IBC PHARMACEUTICALS
发明人:
CHANG, CHIEN-HSING,GOLDENBERG, DAVID M.
申请号:
EP12854231
公开号:
EP2785382A4
申请日:
2012.11.29
申请国别(地区):
EP
年份:
2015
代理人:
摘要:
The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK(TM) (DNL(TM)) complex. Preferably, the DNL(TM) complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-alpha2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充